Supplementary Online Content
|
|
- Alexandra Natalie Conley
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to PD-L1. JAMA Oncol. Published online August 18, doi: /jamaoncol efigure 1. Schematic Layout (A) and H&E Staining (B) With Lung Tumor (Blue), Tissue Controls (Red), and Cell Line Controls (Green) efigure 2. Representative Images From YTMA 337 of DAB and QIF Immunostaining Including Positive Controls, Placenta, and H820 Cell Line, Negative Control Ramos, and Positive Tumor Staining efigure 3. Signal to Noise Curves Across Range of Concentrations Tested for Four PD-L1 Antibodies in Tumor Cases efigure 4. Concordance of Four PD-L1 Antibodies as Determined by QIF Score Comparison in YTMA337 in Tumor Cases (A) and Cell Lines (B) efigure 5. Schematic Layout of 15-Spot PD-L1 Reference TMA (A) and DAB Staining at Low Power Objective and QIF Staining at High Power Objective of 15-Spot reference PD-L1 IHC TMA for PD-L1 Antibodies (B) efigure 6. Concordance of Four PD-L1 Antibodies as Determined by QIF in Immunostaining (A) and Six PD-L1 Antibodies as Determined by DAB Quantified Membrane Intensity Staining in 15-Spot PD-L1 IHC Reference TMA (B) efigure 7. 28_8 Discordance Between 28_8 Staining on YTMA 337 Over Four Independent Runs and Three Independent Operator (A), Concordance of SP142 Staining as Assessed by Two Independent Operators Over Two Independent Runs in Tumor (Left) and Cell Line Cores (Right) (B), and 28_8 QIF Staining Regressed to SP142 QIF Results Obtained From YTMA 337 c) Representative Images From 28_8 DAB and QIF Staining (C) ematerial. Supplemental Methods and Data This supplementary material has been provided by the authors to give readers additional information about their work.
2 efigure 1. Schematic Layout (A) and H&E Staining (B) With Lung Tumor (Blue), Tissue Controls (Red), and Cell Line Controls (Green)
3 efigure 2. Representative Images From YTMA 337 of DAB and QIF Immunostaining Including Positive Controls, Placenta, and H820 Cell Line, Negative Control Ramos, and Positive Tumor Staining
4 efigure 3. Signal to Noise Curves Across Range of Concentrations Tested for Four PD-L1 Antibodies in Tumor Cases
5 efigure 4. Concordance of Four PD-L1 Antibodies as Determined by QIF Score Comparison in YTMA337 in Tumor Cases (A) and Cell Lines (B)
6 efigure 5. Schematic Layout of 15-Spot PD-L1 Reference TMA (A) and DAB Staining at Low Power Objective and QIF Staining at High Power Objective of 15-Spot reference PD-L1 IHC TMA for PD-L1 Antibodies (B)
7 efigure 6. Concordance of Four PD-L1 Antibodies as Determined by QIF in Immunostaining (A) and Six PD-L1 Antibodies as Determined by DAB Quantified Membrane Intensity Staining in 15-Spot PD-L1 IHC Reference TMA (B)
8 efigure 7. 28_8 Discordance Between 28_8 Staining on YTMA 337 Over Four Independent Runs and Three Independent Operator (A), Concordance of SP142 Staining as Assessed by Two Independent Operators Over Two Independent Runs in Tumor (Left) and Cell Line Cores (Right) (B), and 28_8 QIF Staining Regressed to SP142 QIF Results Obtained From YTMA 337 c) Representative Images From 28_8 DAB and QIF Staining (C)
9 ematerial. Supplemental Methods and Data Introduction Immune therapies targeting programmed cell death 1(PD-1) and its respective ligand, programmed cell death ligand -1 (PD-L1) have demonstrated objective clinical responses in a variety of advanced tumor types, including NSCLC (1-3). The PD-1/PD-L1 immune checkpoint axis is an important co-regulatory system in the immune response which leads to the inactivation/exhaustion of lymphocyte cells (4-6). Its natural function is to down-regulate the immune system response to self-antigens as evidenced by the development of significant autoimmunity in PD-L1 knockout mice (7). While both of the FDA-approved assays show a higher response rate in PD-L1 positive patients, substantial responses have been observed in PD-L1 negative patients (8-10). The definition of PD-L1 positive currently lacks standardization and prediction of response by IHC is limited by the subjective nature of the technique. Variable cutoffs for defining a positive case across trials have been utilized, for instance, the assay coupled with nivolumab uses categories of 0, >1, >5 and >10% cells with membranous staining, while the assay for pembrolizumab uses 0, 1-49, and >50% cells positive (1, 3). To further complicate the situation, atezolimab and avelumab also assess the expression of PD-L1 in the immune cells in the surrounding stroma (11-13). PD-L1 is a single transmembrane protein with IgV-like and IgC-like extracellular domains, as well as a short 31 amino acid cytoplasmic tail at its C terminus (14). Antibodies against both intracellular and extracellular domains are available commercially, and it has been reported that antibodies targeting PD-L1 s cytoplasmic provide clearer membranous staining (15). This discrepancy could be explained by differential expression and/or function of PD-L1 s intra- and extracellular domains. For instance, an RNA splice variant lacking the extracellular IgV domain has been identified though endogenous expression of a corresponding protein isoform, but this has not been verified in any in vitro or animal models (16). Theoretically, cleavage of PD-L1 could account for differences in intracellular and extracellular PD-L1 staining. Unpublished data in our lab suggested antibodies directed at the extracellular domain revealed expression in some cases that were negative for the intracellular domain. However subsequent work suggested that antibody (E1J2J) showed lack of specificity in some common assay conditions and thus is was not included in this study. Methods Tissue Microarray Construction-Yale Index TMA: Retrospectively collected formalin fixed paraffin embedded tissue blocks from 30 patients were obtained from Yale Pathology Archives with a range of expression of PD-L1 as assessed in previous as yet unpublished studies. All cases obtained had signed consent for tissue use under approved human investigation committee protocol # Cell line pellets were processed in an identical manner to tissue in the creation of cell line pellet blocks. Tissue and cell line blocks were prepared in a tissue microarray format containing 0.6 mm representative FFPE cores in two fold redundancy. Controls included, tissue controls; placenta and tonsil and cell line pellets H820, H441, HCC193, H1975, A431, H2882, Karpas 299, Ramos, parental and PD-L1 stably transfected MEL624. Cell lines were purchased from American Type Culture Collection or obtained from other labs (efigure 1). Antibodies: PD-L1 expression was evaluated by chromogenic immunohistochemistry (IHC) and quantitative immunofluorescence (QIF) using five monoclonal antibodies raised against the intracellular and extracellular domain. The intracellular antibodies included the following clones; E1L3N (Cell Signaling Technology, Inc. #13684), SP142 (Spring Bioscience Corp. M4420) and 9A11 (Cell Signaling Technology, Inc. #29122). The extracellular antibodies included; SP263 (Ventana Medical Systems, Inc ), and 28-8 (Abcam plc. Ab205291). Antibodies deemed to pass validation showed positive membrane staining in Karpas 299, H820, H441, HCC193, H1975, A431, H2882 and transfected M624 with no expression in parental cells or Ramos; as well as membranous staining of the syncytiotrophoblast layer of the placenta, while showing absence in the stromal and vascular regions. Quantitative Immunofluorescence: TMA slides were soaked in xylene twice for 20 minutes each. Slides were rehydrated in two 1-minute washes in 100% ethanol followed by one wash in 70% ethanol and rinsed in streaming tap water for 5 minutes. Antigen retrieval was performed in EDTA, ph 8 in the Lab Vision PT module. Buffers were preheated to 85 C before slide addition and then heated to sub-boiling 97 C for 20 mins. Endogenous peroxidases were blocked by 30-minute incubation in 2.5% hydrogen peroxide in methanol. Nonspecific antigens were blocked using a 0.3% BSA in TBST for 30 minutes. Primary antibodies were incubated at concentrations described in Table 1 (main text) and 1:100 pan-cytokeratin (Clone AE1/AE3 Dako) overnight at 4 C except for SP263 which was incubated for 20 minutes at 37 C followed by 1hr incubation with pan-cytokeratin. Following this the slides were
10 incubated with Alexa 546-conjugated goat anti mouse secondary antibody (Life Technologies) 1:100 diluted in rabbit EnVision reagent (Dako K4009) for 1 hr at RT. Target signal was amplified using Cy5-Tyramide (Perkin Elmer SAT705A001EA) for 10 mins. Finally, TMAs were stained with 1:500 DAPI for 10 mins at RT and mounted with Prolong Gold antifade mounting reagent (Life Technologies P36394). Immunofluorescence was quantified using automated quantitative analysis (AQUA) on all regions of tissue on each slide as previously described (17). Briefly, fluorescent images of DAPI, Cy3 (Alexa 546-cytokeratin), and Cy5 (PD-L1) for each core were collected. Image analysis was carried out using the AQUAnalysis software (Genoptix), which is generated for each compartment by dividing the sum of target pixel intensities by the area of the compartment in which the target is measured. Quantitation of chromogenic IHC: Chromogenic IHC was quantified using the Aperio Positive Pixel Count based on the intensity of membrane staining of respective PD-L1 antibodies. Intensity as defined in this instance is proportional to the amount of light transmitted through the slide with values ranging from Intensity values determined from Positive Pixel Count were subtracted from highest possible intensity (255) to create a directly proportional distribution of membrane intensity for each antibody. Results YTMA index array as a standardized PD-L1 array In an effort to comparatively assess the measurement of PD-L1 across antibodies we constructed a PD-L1 specific index array called YTMA 337 using tumors and cell lines (efigure 1). Both chromogenic and fluorescent immunostaining were performed. Representative DAB and QIF images of control tissue (placenta), cell lines (H820 and Ramos) and tumor tissue are shown in efigure 2. Lack of staining in Ramos cell lines and Mel624 WT which are known negatives for PD-L1 was used to confirm specificity of all antibodies tested in this analysis. As expected all staining observed in the controls and tumor tissue was membranous in accordance with known cellular location of PD-L1. Positive staining of PD-L1 was observed in both tumor and stroma of lung cancer cases however only positive staining in tumor was used for determination of optimal antibody concentration. To determine the optimal antibody concentration for each antibody, we used an algorithm which determines the adjusted signal to noise, based on QIF where signal to noise is calculated by dividing the to 10% of cases by the bottom 10% of cases (assumed to represent noise) then multiplied by the dynamic range as calculated by the difference between the mean of the top and bottom 10% of cases. The optimal concentrations of each of the antibodies in our QIF assay were determined by testing antibody concentrations ranging from one log above to one log below the manufacturers recommended concentration (except for SP263 which was only obtainable in prediluted form). Optimal concentrations, selected based on the adjusted signal to noise ratio were, 3.4, and 1.0 µg/ml for E1L3N, SP142 and 9A11 respectively (efigure 3). SP263 is currently only available as a prediluted antibody at 1.61 µg/ml, therefore we were limited in the dilutions we could perform however we tittered SP263 at three concentrations below the prediluted concentration. At 1.61 μg/ml SP263 demonstrated the highest adjusted signal to noise indicating that optimal concentration may be either the pre-diluted concentration or above, however we were unable to confirm due to lack of concentrated antibody showed a lack of reproducibility under QIF conditions in a standard QIF staining protocol (Day 1-3) with Kappa co-efficient ranging from to 0.16 (efigure 4A). We additionally included an assay performed on Bond Rx as per Abcam guidelines (Day 4 Operator 3) and regressed to SP142 (efigure 4B) for cell lines and tumors. Regressions between SP142 and 28-8 tested on Bond Rx were 0.44 and 0.56 for tumor and cell line cores respectively. Representative Images from 28-8 immunostaining are shown in efigure 4C results were reproducible under DAB staining of 15 Spot CLMA are described in main text. Representative examples of the DAB for all antibodies is shown in efigure 5 Chromogen-based assessment of PD-L1 antibody concordance As demonstrated above 28-8 results were only reproducible under DAB staining conditions. To include this antibody in our comparisons, we utilized the Aperio Positive Pixel counter and assessed DAB staining of the Horizon 15 Spot CLMA array. All staining was carried out in a single run on the Bond Rx as described in materials and methods. Using this method, all five antibodies (E1l3N, SP142, 9A11, SP263 and 28-8) showed high levels of concordance (discussed in main text). A schematic of this array and representative images is shown in efigure 5. Similarly, antibody 22c3 was evaluable only using the Dako Link 48 platform. A single CLMA slide was run on
11 this platform exactly according to manufacturer s instructions. Quantification was the same as that used for 28-8 and the other DAB visualized specimens. ereferences 1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26): Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti PD-1 Antibody in Cancer. New England Journal of Medicine. 2012;366(26): Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology. 2014;32(10): Chen Daniel S, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. 2013;39(1): He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports. 2015;5: Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. 2004;101(29): Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. 2013;108(8): Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21): Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba, II, Hirsch FR, et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015;10(7): Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti Programmed Death 1 Antibody, BMS , ONO-4538) in Patients With Previously Treated Advanced Non Small-Cell Lung Cancer. Journal of Clinical Oncology Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J-C, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO Meeting Abstracts. 2013;31(15_suppl): Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2013;31(15_suppl): Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12): Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, et al. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer immunology research. 2015;3(12): He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PD-L1 mrna encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin. 2005;26(4): McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal of the National Cancer Institute. 2005;97(24):
Supplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy
VENTANA PD-L1 (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA PD-L1 (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA PD-L1 (SP142) Assay Identify patients most
More informationVENTANA PD-L1 (SP142) Assay
VENTANA (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess UC patient benefit from TECENTRIQ
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationBiomarkers for Cancer Immunotherapy Debate
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationSupplementary Online Content
Supplementary Online Content Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationImmune Cell Phenotyping in Solid Tumors using Quantitative Pathology
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationInterpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use
Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use For countries outside of the United States, see the local
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationProgrammed Death-Ligand 1 Immunohistochemistry in Lung Cancer
State of the Art: Concise Review Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art? Keith M. Kerr, MBChB, FRCPath,* Ming-Sound Tsao, MD, PhD, Andrew G. Nicholson,
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationAnti-PD-L1 antibody [28-8] ab205921
Anti-PD-L1 antibody [28-8] ab205921 2 Abreviews 16 References 15 Images Overview Product name Anti-PD-L1 antibody [28-8] Description Tested applications Species reactivity Immunogen Rabbit monoclonal [28-8]
More informationEvaluation of the efficacy and safety of anti-pd-1 and anti-pd-l1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis
Original Article Evaluation of the efficacy and safety of anti-pd-1 and anti-pd-l1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis Minghan Jia 1,2,3 *, Weijiao Feng 1,2,3
More informationAssessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
Original Article Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer Chen Pang 1 *, Limei Yin 1 *, Xiaojuan Zhou 1 *,
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationMultiplicity and other issues related to biomarker-based oncology trials ASA NJ Chapter
Multiplicity and other issues related to biomarker-based oncology trials ASA NJ Chapter Keaven M. Anderson, Christine K. Gause, Cong Chen Merck Research Laboratories November 11, 2016 With thanks to Eric
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationCheckpoint inhibitors in the first-line treatment of non-small cell lung cancer
380 Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer L. Decoster, MD 1, K. Vekens, MD 2, S. Mignon, MD 1, D. Schallier, MD, PhD 1, J. De Grève, MD, PhD 1 SUMMARY Antibodies
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationDevelopment of a Companion Diagnostic for Pembrolizumab in Non Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Development of a Companion Diagnostic for Pembrolizumab in Non Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1 Marisa Dolled-Filhart, PhD; Charlotte Roach, BS; Grant Toland,
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationGeneral Laboratory methods Plasma analysis: Gene Expression Analysis: Immunoblot analysis: Immunohistochemistry:
General Laboratory methods Plasma analysis: Plasma insulin (Mercodia, Sweden), leptin (duoset, R&D Systems Europe, Abingdon, United Kingdom), IL-6, TNFα and adiponectin levels (Quantikine kits, R&D Systems
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor
More informationExploring the PD-L1 Pathway
Active Within the tumor microenvironment Steps 1-3: Initiating and propagating anticancer immunity 1 may inhibit T-cell activity in the tumor microenvironment Dendritic cells capture cancer and then prime
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationDeciphering the biology that drives response to immunotherapy
Deciphering the biology that drives response to immunotherapy Phenoptics TM Quantitative Pathology Platform Trent Norris, Field Application Scientist September 15, 2016 HUMAN HEALTH ENVIRONMENTAL HEALTH
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationTITLE: Evaluation of Biomarkers Predictive of Benefit From PD-1 Inhibitor MK-3475 in Patients with Non-Small Cell Lung Cancer and Brain Metastases
AWARD NUMBER: W81XWH-15-1-0203 TITLE: Evaluation of Biomarkers Predictive of Benefit From PD-1 Inhibitor MK-3475 in Patients with Non-Small Cell Lung Cancer and Brain Metastases PRINCIPAL INVESTIGATOR:
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationPepsin Solution ready-to-use
SIE HABEN DIE VISION, WIR HABEN DIE SUBSTANZ. Pepsin Solution Single component Pepsin Solution: only one component refrigerator stable Pepsin is a commonly used digestive enzyme for immunohistochemical
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationProduct Datasheet. EMMPRIN/CD147 Antibody (MEM-M6/1) NB Unit Size: 0.1 mg. Store at 4C. Do not freeze. Publications: 2
Product Datasheet EMMPRIN/CD147 Antibody (MEM-M6/1) NB500-430 Unit Size: 0.1 mg Store at 4C. Do not freeze. Publications: 2 Protocols, Publications, Related Products, Reviews, Research Tools and Images
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationUrothelial Carcinoma (UC)
EDUCATION PD-L1 IHC 28-8 pharmdx Interpretation Manual Urothelial Carcinoma (UC) For In Vitro Diagnostic Use Table of Contents Introduction...5 Intended Use in Urothelial Carcinoma...5 How to Use the
More informationHistopathology 2016 DOI: /his.13056
Histopathology 216 DOI:.1111/his.1356 Validated programmed cell death ligand 1 immunohistochemistry assays ( and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationNSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA
Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization
More informationPD-L1 Expression, Role, and Significance in Lung Pathology. Ross A Miller, MD FACP FASCP
PD-L1 Expression, Role, and Significance in Lung Pathology Ross A Miller, MD FACP FASCP Background information PD-1 and PD-L1 expression in tissues PD-L1 Ligand to PD-1 (PD-1 on T cells) Rarely expressed
More informationProteoScan Cancer Lysate Arrays. QC and Validation Data
ProteoScan Cancer Lysate Arrays QC and Validation Data 4.5 mm Barcode Cancer Lysate Array Layout PA02 60 mm B1 C2 K3 Ly1 O2 P3 Mel1 Lv2 St3 B2 C3 L1 Ly2 O3 Pr1 Mel2 Lv3 B3 K1 L2 Ly3 P1 Pr2 Mel3 St1 C1
More informationEvaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a metaanalysis
Original Article Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a metaanalysis Yang-Bo Hu 1 *, Qun Zhang 2,3 *, Hui-Juan Li 4,
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationStrengths and Weaknesses of PD-L1 testing: Pathology perspective
Strengths and Weaknesses of PD-L1 testing: Pathology perspective Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Foresterhill, Aberdeen Disclosures
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationTITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma
TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Ms Amy Newman, Ms Suzanne Parry, Mrs Dawn Wilkinson, Dr Tony O Grady, Dr Perry Maxwell, Mr David
More informationAccepted Manuscript. Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Patricia M. Santos, Lisa H. Butterfield
Accepted Manuscript Next Steps for Immune Checkpoints in Hepatocellular Carcinoma Patricia M. Santos, Lisa H. Butterfield PII: S0016-5085(18)35218-1 DOI: https://doi.org/10.1053/j.gastro.2018.11.008 Reference:
More informationUrothelial Carcinoma (UC)
EDUCATION PD-L1 IHC 28-8 pharmdx Interpretation Manual Urothelial Carcinoma (UC) PD-L1 IHC 28-8 pharmdx is FDA-approved for In Vitro Diagnostic Use Table of Contents Introduction...5 Intended Use in Urothelial
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationPD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes H. R. Ali 1,2, S-E. Glont 1, F. M. Blows 3, E. Provenzano 4,5, S-J. Dawson
More informationThe Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia
VASCULAR CELL OPEN ACCESS ORIGINAL RESEARCH The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia Pagliuso Julia, Parry Suzanne, Haffajee Zenobia, Badrick Tony, Miller Keith,
More informationA case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
Int Canc Conf J (6) 5:9 96 DOI.7/s369-6-56-8 CASE REPORT A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis Shun-Ichiro Kageyama Shigeo Yamaguchi Shin Ito Yoshiyuki
More informationCarcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationGaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017
Gaining New Insights Through IF Multiplexed Staining and Analysis Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory Assessing more from Tissue Sections Gaps with More Common Methods Most common
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationVEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization
Cell Reports, Volume 9 Supplemental Information VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization Sharon Lim, Yin Zhang, Danfang Zhang, Fang Chen,
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationSupplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in
Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in nulliparous (left panel) and InvD6 mouse mammary glands (right
More informationCompanion & Complementary Diagnostics: Clinical and Regulatory Perspectives
Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives Workshop on Companion Diagnostics January 31, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute Fredensborg, Denmark
More informationImmunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on
Supplemental Methods Immunohistochemical Analyses Immunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on prostatectomy sections obtained post-study. Briefly,
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationNext-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry
Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry
More informationPD-L1 IHC 22C3 pharmdx. SK tests for use with Autostainer Link 48 Table of Contents
PD-L1 IHC 22C3 pharmdx SK006 50 tests for use with Autostainer Link 48 Table of Contents 1 Intended Use... 2 2 Summary and Explanation... 2 2.1 NSCLC... 2 2.2 Gastric or Gastroesophageal Junction (GEJ)
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationUtilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint
APPLICATION NOTE AlphaLISA Technology Authors: Matthew Marunde Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint Introduction
More information